

FILE COPY

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/853,895
Filing Date May 14, 2001
First Named Inventor Yuanxiang TAO et al.
Group Art Unit ~~1644~~ 1635
Examiner Name TBA
Attorney Docket Number 001107.00130

Use as many sheets as necessary)

Sheet 1 of 1

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
KAL		CA 2,273,622	12/02/00	TYMIANSKI		
KAL		WO 97/33173	09/12/97	UNIV. OF CAL.		
KAL		WO 97/46877	12/11/97	UNIV. OF EDINBURGH		
KAL		WO 99/37768	07/29/99	JOHNS HOPKINS		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KAL		Woolf C.J., et al., <u>Pain</u> , "The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states", 44, pp. 293-299 (1991)	
KAL		Ishizaki, K. et al., <u>Can. J. Anesth.</u> , "Intrathecal administered NMDA receptor antagonists reduce the MAC of isoflurane in rats", 43:7, pp. 724-730 (1996)	
KAL		Sattler, R., et al., <u>Science</u> , "Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein", 284, pp. 1845-1848 (1999)	
KAL		Brenman, J.E., et al., <u>The Journal of Neuroscience</u> , "Cloning and characterization of postsynaptic Density 93, a nitric oxide synthase interacting protein", 16(23), pp. 7407-7415 (1996)	
KAL		Tao, Y.X., et al., <u>Neuroscience</u> , "Expression of PSD-95/SAP90 is critical for N-methyl-D-aspartate receptor-mediated thermal hyperalgesia in the spinal cord", 98:2, pp. 201-306 (2000)	
KAL		Tao, F. et al., <u>Neuroreport</u> , "Knockdown of PSD-95/SAP90 delays the development of neuropathic pain in rats", 12:15, pp. 3251-3255 (2001)	
KAL		Tao, Y.-X., et al., <u>Anesthesiology</u> , "Effect of the deficiency of spinal PSD95/SAP90 on the minimum alveolar anesthetic concentration of isoflurane in rats", 94:6, pp. 1010-1015 (2001)	

Examiner Signature	<i>Karen A. Jacobson</i>	Date Considered	02-25-03
--------------------	--------------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.